TABLE II.
Mean health utility scores (hus) between treatments, per encounter
| Current drug | Stable disease | Progressing disease | |||
|---|---|---|---|---|---|
|
|
|
||||
| Encounters (n) | Mean hus | p Valuea | Encounters (n) | Mean hus | |
| Crizotinib | 107 | 0.812 | Reference | 30 | 0.779 |
|
| |||||
| Ceritinib | 110 | 0.805 | 0.75 | 16 | 0.752 |
|
| |||||
| Alectinib | 37 | 0.852 | 0.08 | 10 | 0.838 |
|
| |||||
| Brigatinib | 21 | 0.834 | 0.20 | 10 | 0.707 |
|
| |||||
| Lorlatinib | 17 | 0.832 | 0.56 | 3 | 0.799 |
|
| |||||
| Single-agent CTxb | 37 | 0.827 | 0.60 | 16 | 0.729 |
a
By t-test, compared with crizotinib.
b
Because of small numbers, no data are presented for 7 platinum doublet chemotherapy encounters.